A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies

Inclusion Criteria: * Histologically confirmed CD30-positive hematologic malignancy. * Patients with HL must have failed systemic chemotherapy. * Patients with other CD30-positive malignancies (including ALCL) must be beyond first remission or refractory to front line chemotherapy. * Patients must have measurable disease of at least 1.5 cm as documented by radiographic technique. Exclusion Criteria: * Current diagnosis of primary cutaneous ALCL (systemic ALCL eligible). * History of allogeneic stem cell transplant. * Patients who have had previous treatment with any anti-CD30 antibody.